UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________ FORM 10-K ________________________________________________________________________ Table of Contents (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 3, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Co ...

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an ...

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an ...

Core Viewpoint - Danaher (DHR.N) announced a cash acquisition of Masimo (MASI.OQ) for approximately $9.9 billion, with a purchase price of $180 per share, representing a 38% premium over Masimo's closing price on February 13. The deal aims to strengthen Danaher's position in the patient monitoring sector, but concerns over high valuation and short-term financial pressure have led to a decline in Danaher's stock price following the announcement [1]. Stock Performance - Following the acquisition announcement, Danaher's stock experienced volatility and a downward trend. On February 17, the stock fell by 2.93% to $206.36, with a significant trading volume of $1.791 billion and a price fluctuation of 3.66%. By February 19, the stock closed at $209.40, marking a cumulative decline of 2.58% over the week, with a total price range of 8.26% and a low of $201.00 on February 17. During the same period, the life sciences sector declined by 0.80%, and the Nasdaq index fell by 0.54%, impacting individual stock performance [2]. Financial Report Analysis - Danaher reported better-than-expected Q4 2025 results at the JPMorgan Healthcare Conference on February 13, with revenues of $6.838 billion, a year-over-year increase of 4.5% (core growth of 2.5%), and adjusted earnings per share of $2.23, up 4% year-over-year. Management highlighted an 8.8% growth in the biotechnology segment and provided guidance for 2026, projecting core revenue growth of 3%-6% and an operating margin expansion of over 100 basis points, emphasizing growth will depend on the recovery of the life sciences market and a rebound in diagnostic demand from China [3]. Institutional Perspectives - Analysts have mixed views on the acquisition. JPMorgan analysts believe that acquiring Masimo deviates from Danaher's traditional core areas and may exert short-term pressure on the stock price, but they acknowledge its long-term synergy potential. Bernstein analyst Christian Moore anticipates that post-acquisition, Masimo will contribute an incremental $0.15-$0.20 to Danaher's earnings per share in the first year, rising to approximately $0.70 by the fifth year, viewing it as a strategic acquisition in the long run. Additionally, February data shows that 89% of institutions maintain a "buy" or "hold" rating, with an average target price of $264.18 [4].

Company Overview - Masimo is a global medical technology company known for its innovative monitoring technologies, including pulse oximetry, which is used on over 200 million patients annually [5] - The company went public in August 2007 at $17 per share and reached a high of $305.21 in November 2021, but experienced a decline of over 60% in the following months [6][9] Acquisition Details - Masimo has entered into a definitive agreement to be acquired by Danaher for $9.9 billion, with Danaher offering $180 in cash per share [1][8] - The acquisition has been unanimously approved by the boards of both companies and is expected to close in the second half of 2026, pending regulatory approvals [2] - Post-acquisition, Masimo will operate as a standalone business unit within Danaher's Diagnostics segment, enhancing Danaher's offerings in acute care settings [2][8] Financial Performance - Following the acquisition announcement, Masimo's shares surged nearly 35%, and over the past six months, the shares have risen 19.6%, contrasting with a 7% decline in the industry [3] - For Q4 2025, Masimo reported preliminary sales of $411 million, reflecting a 12% increase, with full-year revenues expected to be approximately $1.523 billion, indicating a 9% growth [14][15] Industry Prospects - The global pulse oximeter market was valued at approximately $3.34 billion in 2023 and is projected to grow at a CAGR of 6.9%, reaching about $5.33 billion by 2030, driven by increasing respiratory and cardiovascular diseases [12] - The demand for continuous monitoring devices, including pulse oximeters, is expected to rise due to technological advancements and the growing adoption of home healthcare [12][13]

Masimo Founder Joe Kiani On The Healthtech Company’s $10 Billion Acquisition https://t.co/twE5qYVHnH (📸: Ethan Pines for Forbes) https://t.co/LPKl8nJPaO ...

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Masimo Corporation to Danaher Corporation, focusing on the adequacy of the $180.00 cash offer per share for Masimo shareholders [1] Company Overview - Masimo Corporation is set to be acquired by Danaher Corporation under a proposed transaction where shareholders will receive $180.00 in cash for each share they own [1] Investigation Details - The law firm Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is assessing whether the sale price adequately reflects the value of Masimo Corporation and the process leading to this valuation [1]

Core Viewpoint - Masimo (MASI) shares experienced a significant increase of 34.2% to close at $174.69, driven by a definitive acquisition agreement with Danaher Corporation valued at $180 per share, totaling approximately $9.9 billion [1][2]. Company Summary - The acquisition of Masimo by Danaher Corporation is an all-cash transaction, with completion expected in the second half of 2026, pending regulatory approvals and customary closing conditions [2]. - Masimo is projected to report quarterly earnings of $1.43 per share, reflecting a year-over-year decline of 20.6%, with revenues anticipated at $409.06 million, down 31.9% from the previous year [3]. - The consensus EPS estimate for Masimo has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. Industry Context - Masimo is categorized under the Zacks Medical - Instruments industry, where UFP Technologies (UFPT) is another player, closing at $246.13 with a recent return of -5.7% over the past month [5]. - UFP Technologies has a consensus EPS estimate of $2.26, unchanged over the past month, representing an 8.1% decline from the previous year [6].

Group 1 - Danaher announced the acquisition of Masimo for $9.9 billion, expanding its presence in the patient monitoring equipment sector, with a valuation of $180 per share, representing a 38.3% premium over Masimo's previous closing price [1] - Danaher, valued at $150 billion, is primarily focused on drug development and testing tools, marking this acquisition as a new venture outside its core business [1] - Masimo specializes in non-invasive monitoring devices for hospitals, including pulse oximeters and brain activity monitors, and has been in the spotlight due to patent disputes with Apple [1] Group 2 - The acquisition will enhance Danaher's diagnostic product matrix by integrating Masimo's non-invasive monitoring devices with its existing invasive Radiometer blood analysis product line [2] - Danaher expects an increase in adjusted diluted earnings per share by $0.15 to $0.20 in the first full fiscal year post-acquisition, and approximately $0.70 by the fifth full fiscal year, with the deal anticipated to close in the second half of 2026 [2] - The transaction is expected to generate over $125 million in annual cost synergies [2]

And right now we are 2 minutes away from the end of the trading day. Romaine Bostick here alongside Katie Greifeld, taking you through to that closing bell with a global simulcast. Carol Massar Tim Stenovec Join us now as we welcome our audiences across all of our Bloomberg platforms, Television, radio, our partnership with you to the past, the most crucial moments here in the trading day.Carol Massar ten. Senator, great to see you once again here on this Tuesday afternoon. Did you bring us back any Olympic ...